查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1318925

呼吸道疾病疫苗市場：依感染疾病、類型、年齡層別分類 - 全球預測 2023-2030 年

Respiratory Disease Vaccine Market by Infection, Type, Age Group - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球呼吸道疾病疫苗市場預計到2023年將大幅成長234.2億美元，年複合成長率為5.85%，到2030年將達到驚人的349.3億美元。

FPNV定位矩陣

FPNV定位矩陣對於評估全球呼吸道疾病疫苗市場至關重要。透過檢查業務策略和產品滿意度的關鍵指標，我們對供應商進行全面評估，使您能夠根據您的特定需求做出明智的資訊。這種進階分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市佔率分析

市場佔有率分析可以深入了解供應商在特定市場領域的當前地位。比較供應商對整體收入、基本客群和其他關鍵指標的貢獻，可以幫助公司更好地了解自家公司在爭奪市場佔有率時的表現以及面臨的情況。該分析還揭示了特定行業的競爭程度、累積和合併的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細資訊，並分析其在成熟市場的滲透率。

3. 市場多元化：提供有關新產品發布、未開發領域、最新發展和投資的詳細資訊。

4.市場趨勢：全面了解COVID-19、俄羅斯-烏克蘭衝突和高通膨的累積影響。

5.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、法規狀況、專利狀況、製造能力等進行綜合評估。

6. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告回答了以下問題：

1.全球呼吸道疾病疫苗市場規模及預測為何？

2.在預測期內，COVID-19對全球呼吸道疾病疫苗市場的阻礙因素與影響有哪些？

3. 在預測期內，全球呼吸道疾病疫苗市場需要投資哪些產品/細分市場/用途/領域？

4.全球呼吸道疾病疫苗市場的競爭策略為何？

5. 全球呼吸道疾病疫苗市場的技術趨勢和法律規範是什麼？

6.全球呼吸道疾病疫苗市場主要廠商的市佔率為何？

7. 哪些型態和策略措施被認為適合進入呼吸道疾病疫苗全球市場？

目錄

第1章 前言

第2章 調查方法

第3章 執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 促進因素
      • 呼吸道疾病盛行率增加
      • 臨床試驗和疫苗開發正在進行中
      • 政府支持呼吸健康的配合措施
    • 抑制因素
      • 交付基礎設施不足且意識有限
    • 機會
      • 主要企業研發費用增加
      • 透過轉售合作增加疫苗的供應
    • 任務
      • 消費者對呼吸道疾病疫苗的信任與信心
  • 市場趨勢
  • COVID-19 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法律規範
  • 客戶客製化
    • 新型冠狀病毒：專注於積極的疫苗開發

第6章 呼吸道疾病疫苗市場：依感染疾病

  • 介紹
  • 流感病毒
  • 百日咳
  • 肺炎鏈球菌
  • 結核

第7章 呼吸系統疾病疫苗市場：依類型

  • 介紹
  • 細菌疫苗
  • 聯合疫苗
  • 病毒疫苗

第8章 呼吸道疾病疫苗市場：依年齡層別

  • 介紹
  • 青年
  • 成人
  • 嬰兒

第9章 美洲呼吸道疾病疫苗市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章 亞太呼吸道疾病疫苗市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章歐洲、中東和非洲呼吸道疾病疫苗市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭形勢

  • FPNV定位矩陣
  • 市佔率分析：主要企業
  • 競爭情境分析：主要企業

第13章上市公司名單

第14章附錄

  • 討論指南
  • 關於許可證和定價
Product Code: MRR-035AB9C0DAB1

The Global Respiratory Disease Vaccine Market is forecasted to grow significantly, with a projected USD 23.42 billion in 2023 at a CAGR of 5.85% and expected to reach a staggering USD 34.93 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Respiratory Disease Vaccine Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Respiratory Disease Vaccine Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Infection, market is studied across Influenza Virus, Pertussis, Streptococcus Pneumoniae, and Tuberculosis. The Streptococcus Pneumoniae is projected to witness significant market share during forecast period.

Based on Type, market is studied across Bacterial Vaccine, Combination Vaccine, and Viral Vaccine. The Viral Vaccine is projected to witness significant market share during forecast period.

Based on Age Group, market is studied across Adolescent Vaccination, Adult Vaccination, and Infant Vaccination. The Adolescent Vaccination is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Respiratory Disease Vaccine Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Respiratory Disease Vaccine Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Respiratory Disease Vaccine Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Respiratory Disease Vaccine Market?

4. What is the competitive strategic window for opportunities in the Global Respiratory Disease Vaccine Market?

5. What are the technology trends and regulatory frameworks in the Global Respiratory Disease Vaccine Market?

6. What is the market share of the leading vendors in the Global Respiratory Disease Vaccine Market?

7. What modes and strategic moves are considered suitable for entering the Global Respiratory Disease Vaccine Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Respiratory Disease Vaccine Market, by Infection, 2022 vs 2030
  • 4.3. Respiratory Disease Vaccine Market, by Type, 2022 vs 2030
  • 4.4. Respiratory Disease Vaccine Market, by Age Group, 2022 vs 2030
  • 4.5. Respiratory Disease Vaccine Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of respiratory disorders
      • 5.1.1.2. Clinical trials and vaccines developments in pipeline
      • 5.1.1.3. Government initiatives supporting respiratory health
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of inadequate delivery infrastructure & limited awareness
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing R&D expenditure by leading companies
      • 5.1.3.2. Increase vaccine availability through reselling collaborations
    • 5.1.4. Challenges
      • 5.1.4.1. Consumer trust & confidence in respiratory disease vaccination
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization
    • 5.9.1. COVID: Eye on Proactive Vaccine Development

6. Respiratory Disease Vaccine Market, by Infection

  • 6.1. Introduction
  • 6.2. Influenza Virus
  • 6.3. Pertussis
  • 6.4. Streptococcus Pneumoniae
  • 6.5. Tuberculosis

7. Respiratory Disease Vaccine Market, by Type

  • 7.1. Introduction
  • 7.2. Bacterial Vaccine
  • 7.3. Combination Vaccine
  • 7.4. Viral Vaccine

8. Respiratory Disease Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adolescent Vaccination
  • 8.3. Adult Vaccination
  • 8.4. Infant Vaccination

9. Americas Respiratory Disease Vaccine Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Respiratory Disease Vaccine Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Respiratory Disease Vaccine Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. List of Company Mentioned

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. RESPIRATORY DISEASE VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. RESPIRATORY DISEASE VACCINE MARKET SIZE, 2022 VS 2030
  • FIGURE 3. RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2022 VS 2030 (%)
  • FIGURE 5. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 6. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2022 VS 2030 (%)
  • FIGURE 7. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 8. RESPIRATORY DISEASE VACCINE MARKET DYNAMICS
  • FIGURE 9. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 17. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. RESPIRATORY DISEASE VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. RESPIRATORY DISEASE VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 5. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFLUENZA VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY PERTUSSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STREPTOCOCCUS PNEUMONIAE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY BACTERIAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COMBINATION VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY VIRAL VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 14. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADOLESCENT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY ADULT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFANT VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. ARGENTINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. BRAZIL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. CANADA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MEXICO RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. INDIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDONESIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. JAPAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. MALAYSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. PHILIPPINES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. SINGAPORE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SOUTH KOREA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. TAIWAN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. THAILAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. VIETNAM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. DENMARK RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. EGYPT RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. FINLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FRANCE RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. GERMANY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. ISRAEL RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ITALY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. NETHERLANDS RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NIGERIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NORWAY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. POLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. QATAR RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. RUSSIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SAUDI ARABIA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH AFRICA RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SPAIN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SWEDEN RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWITZERLAND RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TURKEY RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED ARAB EMIRATES RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY INFECTION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED KINGDOM RESPIRATORY DISEASE VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. RESPIRATORY DISEASE VACCINE MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 145. RESPIRATORY DISEASE VACCINE MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 146. RESPIRATORY DISEASE VACCINE MARKET LICENSE & PRICING